OncoPharm Carfilzomib
Jan 13, 2022
Dive into the world of carfilzomib, a key player in the fight against multiple myeloma. Discover its unique mechanism of action and how it stacks up against bortezomib. The discussion highlights important dosing strategies and potential side effects. Recent studies are also examined, aimed at improving patient outcomes and clinical practices. It's an insightful exploration of innovative treatments in oncology!
AI Snips
Chapters
Transcript
Episode notes
Proteasome Inhibition Strategy
- Proteasome inhibitors target myeloma cells which produce excessive abnormal proteins.
- Inhibiting proteasome causes toxic protein buildup leading to myeloma cell death by apoptosis.
Carfilzomib's Unique Mechanism
- Carfilzomib irreversibly inhibits the proteasome, unlike bortezomib's reversible inhibition.
- This selectivity and irreversibility could mean higher potency and less off-target effects.
Infuse Carfilzomib Slowly
- Administer carfilzomib infusion over 30 minutes instead of 10 minutes to reduce toxicity.
- Slower infusion decreases peak drug concentration, improving safety without reducing effectiveness.